Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) identifies, develops and markets drugs for the treatment of hematological diseases, cancer, neurological disorders, and psychiatric disorders. The company’s product portfolio includes Xyrem, Xywav, Sunosi, Erwinaze/Erwinase, Defitelio/defibrotide, Vyxeos, Zepzelca, and Other.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s research and development (R&D) efforts focus on evolving and expanding its operations in neuroscience and oncology areas, including its expansion into movement disorders and solid tumors, and exploring and investing in other fields that could further diversify its product portfolio. It also seeks to explore new options for patients including small molecule advancements, novel compounds, biologics, and innovative delivery technologies. Its product candidates include Epidolex, Nabiximols in its neuroscience area for the treatment of idiopathic hypersomnia, JZP-150, JZP-385, JZP441 and JZP-324, besides exploring other indications for Sunosi; JZP-458 in its oncology area, exploring other indications for Vyxeos and Defitelio, generating additional clinical data for Vyxeos and Zepzelca, including in combination with other therapeutic agents through its external collaborations. In FY2022, the company spent US$590.5 million on its R&D, which as a percentage of revenue, stood at 16.1% of its revenue.